ClinicalTrials.gg
CompletedNCT04238663Updated Oct 25, 2023Results posted

Pharmacokinetic Study Comparing MB02 And US And EU Avastin® In Healthy Male Volunteers

A Phase 1 interventional study of MB02 (Bevacizumab Biosimilar) and EU approved Avastin® in Healthy Volunteers, sponsored by mAbxience Research S.L.. Completed at 1 site in Germany. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-10-25.

Sponsored by mAbxience Research S.L. (part of Fresenius Kabi) · Phase 1, Interventional, and Other

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Sep 2019, registered Jan 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
115
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

Randomized, double blind, parallel group, single dose, 3 arm study to investigate and compare the pharmacokinetics (PK), safety and immunogenicity profile of MB02 with US and EU Avastin® in healthy male subjects.

During the course of the study, the similarity in pharmacokinetics will be assessed by sampling the levels of drug in the blood, and by comparing these levels among the different administration arms. Safety, tolerability, and immunologic response to the administered drugs will also be evaluated throughout.

Read the detailed description

The primary PK parameter endpoints are Cmax and AUC(0-∞) for bevacizumab. The secondary PK endpoints will include all other PK parameters for bevacizumab, including tmax, t1/2, CL and AUC(0-t).

The serum PK parameters of bevacizumab will be calculated using standard noncompartmental methods. An analysis of covariance model will be used to analyse the log-transformed primary PK parameters (AUC[0 ∞] and Cmax) and AUC(0-t). The model will include a fixed effect for treatment and body weight as a covariate.

All other PK parameters will not be subject to inferential statistical analysis.

Estimates of geometric mean ratios together with the corresponding 90% confidence intervals (CI) will be derived for the comparisons of the PK parameters as follows:

  • MB02 versus EU Avastin®
  • MB02 versus US Avastin®
  • EU Avastin® versus US Avastin®

PK similarity will be achieved if the 90% CIs for the biosimilar-to-reference ratios of PK endpoints (AUC[0-∞] and Cmax) fall within the predefined 0.80-1.25 acceptance similarity criteria for all 3 pairwise comparisons; MB02 versus EU-approved Avastin®; MB02 versus US-licenced Avastin®; and EU-approved Avastin® versus US-licenced Avastin®.

All AEs will be listed and summarised using descriptive methodology. All observed, or patient-reported AEs will be graded by the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. The incidence of AEs for each treatment will be presented by severity and by association with the study drugs as determined by the Investigator (or designee). Each AE will be coded using the Medical Dictionary for Regulatory Activities. All safety data will be listed and summarised as appropriate.

Immunogenicity data (overall anti-drug antibody [ADA] incidence and titers, and neutralising ADA results) will be listed. A summary of the number and percent of subjects testing positive for ADA or neutralising antibodies (NAB) before the dose of MB02, EU Avastin®, or US Avastin® (Day -1) and at scheduled postdose assessments will be presented by treatment arm. All safety data and immunogenicity data summaries will be based on the safety analysis population. Select analyses may be repeated for subsets with or without ADA and de novo ADA formation as appropriate.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

mAbxience Research S.L. is the lead sponsor of 15 studies on the registry; 1 is open to participants now.

First submitted before mAbxience Research S.L. became part of Fresenius Kabi.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males of any race, between 18 and 55 years of age, inclusive, at Screening.
  2. between 18.5 and 29.9 kg/m2, inclusive, at Screening and Check-in.
  3. Total body weight between 60 and 95 kg, inclusive, at Screening and Check-in.
  4. In good health, determined by no findings from medical history, physical examination, 12-lead , vital sign measurements, and clinical laboratory evaluations (congenital nonhaemolytic hyperbilirubinemia [eg, Gilbert's syndrome] is acceptable) at Screening or Check-in as assessed by the Investigator (or designee).
  5. Relevant clinical laboratory evaluations of haematology, coagulation, urinalysis and clinical chemistry within the following ranges at Screening and Check in. A single repeat test will be allowed at each timepoint.

    • ≥1.5 × 109 L
    • count ≥100 × 109 L
    • >10 g/dl
    • (ALT) and aspartate aminotransferase (AST) ≤
    • Alkaline phosphatase (ALP) ≤1.5 × ULN
    • Total ≤ 1.5 ULN with direct bilirubin \<20% in case of total bilirubin > ULN
    • Blood urea nitrogen ≤1.5 × ULN
    • Creatinine \<132.63 µmol/L
    • Serum albumin: ≥35 g/L
    • Total cholesterol ≤ 7.75 mmol/L
    • Triglycerides ≤ 3.42 mmol/L
    • Creatine kinase (CK) ≤3 × ULN
    • (INR) 0.8 to 1.3
    • Urine dipstick for proteinuria \<2+
  6. Systolic blood pressure ≥90 mmHg and \<140 mmHg and diastolic blood pressure ≥50 mmHg and \<90 mmHg at Screening and Check in.
  7. Subjects agree to use .
  8. Able to comprehend and willing to sign an form (ICF) and to abide by the study restrictions. Subjects must have signed an informed consent before any study-related procedure or evaluation is performed.

Exclusion criteria

Exclusion Criteria:

  1. Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, haematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the Investigator (or designee).
  2. History of significant , intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator (or designee).
  3. Any current or recent history of active infections, including localised infections. (Within 2 months prior Screening Visit for any serious infection which requires hospitalization or intravenous anti-infective, and within 14 days prior Screening Visit for any active infection which requires oral treatment).
  4. History of, or planned surgery, including suturing, dental surgery or wound dehiscence within 30 days of dosing, or within 30 days of the last study visit.
  5. Presence of a nonhealing wound or fracture.
  6. Known history of essential hypertension, orthostatic hypotension, fainting spells or blackouts for any reason, cardiac failure or history of thromboembolic conditions.
  7. Medically significant dental disease or dental neglect, with signs and/or symptoms of local or systemic infection that would likely require a dental procedure during the course of the study.
  8. Clinically relevant history of alcoholism, addiction or drug/chemical abuse prior to Check-in, and/or positive urinary test for alcohol or drugs of abuse at Screening or Check in.
  9. History of bleeding disorders or protein C, protein S, and/or factor V Leiden deficiency.
  10. History of clinically significant haemorrhage, epistaxis, GI bleeding, haemorrhoids and/or haemoptysis.
  11. History of GI perforation, ulcers, gastro oesophageal reflux, inflammatory bowel disease, diverticular disease, or any fistulae.
  12. Alcohol consumption of >24 units per week. One unit of alcohol equals ½ pint (285 mL) of beer or lager, 1 glass (125 mL) of wine, or 1/6 gill (25 mL) of spirits.
  13. Positive hepatitis panel, positive human immunodeficiency test. Subjects whose results are compatible with prior immunisation and not infection may be included at the discretion of the Investigator.
  14. Participation in a clinical study involving administration of an drug (new chemical entity) in the past 90 days prior to Check-in, or within 5 half lives of the investigational drug used in the study.
  15. Use or intend to use slow-release medications/products considered to still be active within 30 days prior to Check-in, unless deemed acceptable by the Investigator (or designee).
  16. Use or intend use of any prescription medications/ nonprescription products known to alter drug absorption, metabolism, or elimination processes, including St. John's wort, within 30 days prior to Check-in, unless deemed acceptable by the Investigator or designee.
  17. Use or intend to use any nonprescription medications/products including vitamins, minerals, and phytotherapeutic/herbal/plant derived preparations within 7 days prior to Check-in, unless deemed acceptable by the Investigator (or designee).
  18. Have received a live or attenuated vaccine from 3 months prior to Screening or have the intention to receive a vaccine during the study.
  19. Intend to travel to a region where a vaccination will be required due to endemic disease within 3 months of dosing.
  20. Previous treatment with an anti VEGF antibody or any other protein or antibody targeting the VEGF receptor.
  21. Use of tobacco- or nicotine-containing products within 1 year prior to Check-in, or positive cotinine test upon Screening or Check-in.
  22. Receipt of blood products within 60 days prior to Check-in.
  23. Donation of blood from 90 days prior to Screening, plasma from 14 days prior to Screening, or from 42 days prior to Screening.
  24. Poor peripheral venous access.
  25. History of abnormal peripheral sensation including paraesthesia and/or numbness in arms and/or legs.
  26. Have previously completed or withdrawn from this study or any other study investigating bevacizumab, and/or have previously received bevacizumab.
  27. Subjects who, in the opinion of the Investigator (or designee), should not participate in this study.
  28. Vulnerable subjects (e.g. persons kept in detention).
  29. Subjects who are study site employees or immediate family members of a study site or Mabxience employee.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
115 participants (actual)

Study arms

  • Experimental
    MB02 (Bevacizumab Biosimilar)

    Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.

    Drug: MB02 (Bevacizumab Biosimilar)

  • Active comparator
    EU approved Avastin®

    Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.

    Drug: EU approved Avastin®

  • Active comparator
    US licenced Avastin®

    Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.

    Drug: US licenced Avastin®

Interventions

  • Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion

  • DrugEU approved Avastin®

    Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion

  • DrugUS licenced Avastin®

    Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion

06

What researchers measure

Primary outcomes

  1. Cmax: Maximum Observed Serum Concentration

    To compare the pharmacokinetic (PK) profiles of MB02, US Avastin® and EU Avastin® (in terms of Cmax) to establish bioequivalence between the 3 study arms. For the PK similarity assessments, regulatory guidelines on bioequivalence were followed whereby two treatments are judged not to be different from one another if the 90% confidence interval (CI) for the geometric LS means ratios are fully contained within the predefined bioequivalence limits of 0.80 to 1.25.

    Time frame: Predose, 1.5 hours (end of infusion), 2, 3, 4, 5, 6, 8, 12, 24 hours post-dose on Day 3-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100.

  2. AUC(0-∞); Area Under the Serum Concentration-time Curve From Time Zero to Infinity

    To compare the pharmacokinetic (PK) profiles of MB02, US Avastin® and EU Avastin® (in terms of AUC\[0-∞\]) to establish bioequivalence between the 3 study arms. For the PK similarity assessments, regulatory guidelines on bioequivalence were followed whereby two treatments are judged not to be different from one another if the 90% confidence interval (CI) for the geometric least square means (GLSM) ratios are fully contained within the predefined bioequivalence limits of 0.80 to 1.25.

    Time frame: Predose, 1.5 hours (end of infusion), 2, 3, 4, 5, 6, 8, 12, 24 hours post-dose on Day 3-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100.

Secondary outcomes

  1. Tmax: Time of Maximum Observed Serum Concentration

    To evaluate and compare the tmax of MB02, US Avastin® and EU Avastin® .

    Time frame: Predose, 1.5 hours (end of infusion), 2, 3, 4, 5, 6, 8, 12, 24 hours post-dose on Day 3-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100.

  2. AUC(0 t)= Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Observable Concentration.

    To evaluate and compare the AUC\[0-t\] of MB02, US Avastin® and EU Avastin®.

    Time frame: Predose, 1.5 hours (end of infusion), 2, 3, 4, 5, 6, 8, 12, 24 hours post-dose on Day 3-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100.

  3. CL: Total Body Drug Clearance After IV Administration

    To evaluate the CL of MB02, US Avastin® and EU Avastin®

    Time frame: Predose, 1.5 hours (end of infusion), 2, 3, 4, 5, 6, 8, 12, 24 hours post-dose on Day 3-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100.

  4. t1/2: Apparent Serum Terminal Elimination Half-life

    To evaluate the t1/2 of MB02, US Avastin® and EU Avastin®

    Time frame: Predose, 1.5 hours (end of infusion), 2, 3, 4, 5, 6, 8, 12, 24 hours post-dose on Day 3-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100.

  5. Immunogenicity: Number of Participants With Anti-bevacizumab Antibodies (Including Neutralizing Antibodies)

    Incidence of anti-bevacizumab antibodies (ADA), including neutralizing antibodies (Nab). Subjects who tested positive at baseline are not included here. Rows for ADA and nAb are not mutually exclusive, i.e. a participant could be included in more than one Row.

    Time frame: Day -1, Day 14, Day 28, Day 56, and Day 78

  6. Number of Participants With Treatment-emergent Adverse Events (Safety)

    Compare the incidence of Treatment-emergent Adverse Events (TEAEs) reported in each treatment arm. TEAEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA version 22.0) and graded using National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v5.0

    Time frame: Day 1 - Day 100

07

Results

Posted Feb 24, 2021

Participant flow

Participant flow — Overall Study
MilestoneMB02 (Bevacizumab Biosimilar)EU Approved Avastin®US Licenced Avastin®
Started383838
Completed383738
Not completed010
Withdrew: Lost to follow-up010

Outcome measures

PrimaryCmax: Maximum Observed Serum Concentration

To compare the pharmacokinetic (PK) profiles of MB02, US Avastin® and EU Avastin® (in terms of Cmax) to establish bioequivalence between the 3 study arms. For the PK similarity assessments, regulatory guidelines on bioequivalence were followed whereby two treatments are judged not to be different from one another if the 90% confidence interval (CI) for the geometric LS means ratios are fully contained within the predefined bioequivalence limits of 0.80 to 1.25.

Time frame:
Predose, 1.5 hours (end of infusion), 2, 3, 4, 5, 6, 8, 12, 24 hours post-dose on Day 3-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100.
Reported as:
Geometric least squares mean · (ng/mL)/(mg/mL)
Cmax: Maximum Observed Serum Concentration
(ng/mL)/(mg/mL)MB02 (Bevacizumab Biosimilar)EU Approved Avastin®US Licenced Avastin®
Cmax: Maximum Observed Serum Concentration86100 ± 24.881100 ± 20.087500 ± 24.9
Statistical analysis
  • MB02 (Bevacizumab Biosimilar) vs EU Approved Avastin® · Ratio of geometric least square mean: 1.06 · 90% CI 0.976 to 1.16For the comparison, MB02 represents the numerator and EU Avastin represents the denominator.
  • MB02 (Bevacizumab Biosimilar) vs US Licenced Avastin® · Ratio of geometric least square mean: 0.983 · 90% CI 0.897 to 1.08
  • EU Approved Avastin® vs US Licenced Avastin® · Ratio of geometric least square mean: 0.926 · 90% CI 0.851 to 1.01For Ratio of geometric least square mean (GLSM): EU is the numerator and US Avastin acts as the denominator
PrimaryAUC(0-∞); Area Under the Serum Concentration-time Curve From Time Zero to Infinity

To compare the pharmacokinetic (PK) profiles of MB02, US Avastin® and EU Avastin® (in terms of AUC\[0-∞\]) to establish bioequivalence between the 3 study arms. For the PK similarity assessments, regulatory guidelines on bioequivalence were followed whereby two treatments are judged not to be different from one another if the 90% confidence interval (CI) for the geometric least square means (GLSM) ratios are fully contained within the predefined bioequivalence limits of 0.80 to 1.25.

Time frame:
Predose, 1.5 hours (end of infusion), 2, 3, 4, 5, 6, 8, 12, 24 hours post-dose on Day 3-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100.
Reported as:
Geometric least squares mean · ng*h/mL
AUC(0-∞); Area Under the Serum Concentration-time Curve From Time Zero to Infinity
ng*h/mLMB02 (Bevacizumab Biosimilar)EU Approved Avastin®US Licenced Avastin®
AUC(0-∞); Area Under the Serum Concentration-time Curve From Time Zero to Infinity30700000 ± 16.228800000 ± 16.430700000 ± 12.9
Statistical analysis
  • MB02 (Bevacizumab Biosimilar) vs EU Approved Avastin® · Ratio of glsm: 1.07 · 90% CI 1.00 to 1.14For the comparison, MB02 represents the numerator and EU Avastin represents the denominator
  • MB02 (Bevacizumab Biosimilar) vs US Licenced Avastin® · Ratio of glsm: 0.998 · 90% CI 0.944 to 1.05For the comparison, MB02 represents the numerator and US Avastin represents the denominator.
  • EU Approved Avastin® vs US Licenced Avastin® · Ratio of glsm: 0.934 · 90% CI 0.884 to 0.988EU Avastin corresponds to the numerator and US Avastin corresponds to the denominator
SecondaryTmax: Time of Maximum Observed Serum Concentration

To evaluate and compare the tmax of MB02, US Avastin® and EU Avastin® .

Time frame:
Predose, 1.5 hours (end of infusion), 2, 3, 4, 5, 6, 8, 12, 24 hours post-dose on Day 3-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100.
Reported as:
Median · hours
Tmax: Time of Maximum Observed Serum Concentration
hoursMB02 (Bevacizumab Biosimilar)EU Approved Avastin®US Licenced Avastin®
Tmax: Time of Maximum Observed Serum Concentration4.0 (1.5 to 8.0)4.0 (1.5 to 11.9)4.0 (1.5 to 12.00)
SecondaryAUC(0 t)= Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Observable Concentration.

To evaluate and compare the AUC\[0-t\] of MB02, US Avastin® and EU Avastin®.

Time frame:
Predose, 1.5 hours (end of infusion), 2, 3, 4, 5, 6, 8, 12, 24 hours post-dose on Day 3-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100.
Reported as:
Geometric least squares mean · ng*h/mL
AUC(0 t)= Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Observable Concentration.
ng*h/mLMB02 (Bevacizumab Biosimilar)EU Approved Avastin®US Licenced Avastin®
AUC(0 t)= Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Observable Concentration.29900000 ± 15.627900000 ± 16.029900000 ± 12.5
SecondaryCL: Total Body Drug Clearance After IV Administration

To evaluate the CL of MB02, US Avastin® and EU Avastin®

Time frame:
Predose, 1.5 hours (end of infusion), 2, 3, 4, 5, 6, 8, 12, 24 hours post-dose on Day 3-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100.
Reported as:
Geometric least squares mean · l/hour
CL: Total Body Drug Clearance After IV Administration
l/hourMB02 (Bevacizumab Biosimilar)EU Approved Avastin®US Licenced Avastin®
CL: Total Body Drug Clearance After IV Administration0.00770 ± 18.10.00823 ± 18.50.00766 ± 16.2
Secondaryt1/2: Apparent Serum Terminal Elimination Half-life

To evaluate the t1/2 of MB02, US Avastin® and EU Avastin®

Time frame:
Predose, 1.5 hours (end of infusion), 2, 3, 4, 5, 6, 8, 12, 24 hours post-dose on Day 3-8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 78, and Day 100.
Reported as:
Geometric least squares mean · hours
t1/2: Apparent Serum Terminal Elimination Half-life
hoursMB02 (Bevacizumab Biosimilar)EU Approved Avastin®US Licenced Avastin®
t1/2: Apparent Serum Terminal Elimination Half-life443 ± 16.9444 ± 14.5458 ± 16.1
SecondaryImmunogenicity: Number of Participants With Anti-bevacizumab Antibodies (Including Neutralizing Antibodies)

Incidence of anti-bevacizumab antibodies (ADA), including neutralizing antibodies (Nab). Subjects who tested positive at baseline are not included here. Rows for ADA and nAb are not mutually exclusive, i.e. a participant could be included in more than one Row.

Time frame:
Day -1, Day 14, Day 28, Day 56, and Day 78
Reported as:
Number · participants
Immunogenicity: Number of Participants With Anti-bevacizumab Antibodies (Including Neutralizing Antibodies)
participantsMB02 (Bevacizumab Biosimilar)EU Approved Avastin®US Licenced Avastin®
ADA positive12149
NAb positive102
SecondaryNumber of Participants With Treatment-emergent Adverse Events (Safety)

Compare the incidence of Treatment-emergent Adverse Events (TEAEs) reported in each treatment arm. TEAEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA version 22.0) and graded using National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v5.0

Time frame:
Day 1 - Day 100
Reported as:
Number · participants
Number of Participants With Treatment-emergent Adverse Events (Safety)
participantsMB02 (Bevacizumab Biosimilar)EU Approved Avastin®US Licenced Avastin®
Subjects with TEAEs302532
Subjects with SAEs000
Subjects discontinued due to TEAEs000
Not related TEAEs161216
Unlikely-related TEAEs424
Possibly related TEAEs101112
TEAEs of mild severity201023
TEAEs of moderate severity10149
TEAEs of severe severity010

Adverse events

Collected over Study duration (Day 1 - Day 100). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MB02 (Bevacizumab Biosimilar)0/38 (0%)0/38 (0%)30/38 (78.9%)
EU Approved Avastin®0/38 (0%)0/38 (0%)25/38 (65.8%)
US Licenced Avastin®0/38 (0%)0/38 (0%)32/38 (84.2%)
Most frequent other events
Showing 10 of 17
Most frequent other events
EventMB02 (Bevacizumab Biosimilar)EU Approved Avastin®US Licenced Avastin®
NasopharyngitisInfections and infestations14/3812/3813/38
HeadacheNervous system disorders5/389/386/38
Back painMusculoskeletal and connective tissue disorders2/386/381/38
Blood Creatine Phosphokinase IncreasedInvestigations3/385/380/38
RhinitisInfections and infestations4/380/380/38
DiarrheaGastrointestinal disorders0/382/383/38
Oropharyngeal painRespiratory, thoracic and mediastinal disorders3/380/381/38
Pulpitis dentalInfections and infestations2/381/382/38
ArthralgiaMusculoskeletal and connective tissue disorders1/382/381/38
FatigueGeneral disorders1/381/382/38

Baseline characteristics

Age, Continuous
Age, Continuous(years)MB02 (Bevacizumab Biosimilar)EU Approved Avastin®US Licenced Avastin®Total
Mean39.4 ± 10.1841.6 ± 11.1038.3 ± 9.6439.8 ± 10.33
Sex: Female, Male
Sex: Female, Male(Participants)MB02 (Bevacizumab Biosimilar)EU Approved Avastin®US Licenced Avastin®Total
Female0000
Male383838114
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)MB02 (Bevacizumab Biosimilar)EU Approved Avastin®US Licenced Avastin®Total
Hispanic or Latino0112
Not Hispanic or Latino383737112
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)MB02 (Bevacizumab Biosimilar)EU Approved Avastin®US Licenced Avastin®Total
American Indian or Alaska Native0000
Asian1214
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White363537108
More than one race1102
Unknown or Not Reported0000
Body mass index (BMI)
Body mass index (BMI)(kg/m^2)MB02 (Bevacizumab Biosimilar)EU Approved Avastin®US Licenced Avastin®Total
Mean24.48 ± 2.72324.59 ± 2.32224.80 ± 2.71224.62 ± 2.573
08

Study locations

1 site
  • Early Phase Clinical Unit (EPCU) PAREXEL International GmbH
    Berlin, 14050, Germany
09

References and documents

Publications

  • Sinn A, Garcia-Alvarado F, Gonzalez V, Huerga C, Bullo F. A randomized, double blind, single dose, comparative study of the pharmacokinetics, safety and immunogenicity of MB02 (bevacizumab biosimilar) and reference bevacizumab in healthy male volunteers. Br J Clin Pharmacol. 2022 Mar;88(3):1063-1073. doi: 10.1111/bcp.15032. Epub 2021 Sep 4. PubMed 34374114 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2019 to primary completion in Mar 2020, 5 months.

Results were first posted in Feb 2021, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2020
First posted
Jan 23, 2020
StartActual
Sep 24, 2019
Primary completionActual
Mar 17, 2020
CompletionActual
Mar 17, 2020
Results first posted
Feb 24, 2021
Last update
Oct 25, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 25, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04238663
Responsible party
Sponsor
First posted
Jan 23, 2020
Start date
Sep 24, 2019
Primary completion
Mar 17, 2020
Completion
Mar 17, 2020
Results posted
Feb 24, 2021
Last update
Oct 25, 2023

Study contacts

Angela Sinn, MD
principal investigator · Early Phase Clinical Unit (EPCU) PAREXEL International GmbH

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MB02

Start the discussion